Real-time nanoscale imaging reveals differences in antibody access to cancer-linked proteins on tiny vesicles

Researchers at Kanazawa University have developed a method to observe how antibodies interact with a cancer-related protein called PD-L1, which is carried on tiny membrane-bound vesicles released by cells. Using high-speed atomic force microscopy, the team found that simply measuring the presence of PD-L1 does not indicate how accessible it is to antibodies.

The study, reported in the journal Small Methods, revealed that cancer-derived vesicles can vary significantly in their ability to present PD-L1 to antibodies. Vesicles from two breast cancer cell lines, MCF7 with low PD-L1 levels and MDA-MB-231 with high PD-L1 levels, showed different antibody interaction patterns. On high PD-L1 vesicles, antibodies frequently docked and remained for longer periods, while on low PD-L1 vesicles, interactions were mostly brief.

This finding suggests that protein accessibility, rather than just its quantity, plays a crucial role in antibody targeting. The Kanazawa University team introduced the Checkpoint Ligand Interface Phenotype (CLIP) framework to categorize vesicles based on antibody binding frequency and duration. This new approach provides a functional picture of how accessible PD-L1 is on individual vesicles, offering a more comprehensive understanding of protein availability for antibody interaction.

The researchers plan to further investigate the CLIP framework using patient-derived vesicles, which could help identify why seemingly similar vesicles exhibit different behaviors and potentially guide the development of more effective cancer treatments. However, the current study should not be interpreted as a direct measure of immune activity or a diagnostic tool.